Adam Stone is an Independent Director of the Company. Mr. Stone is currently the Chief Investment Officer of Perceptive Advisors, a life science focused hedge fund, where he has worked since May 2006. Mr. Stone received a B.A. from Princeton University. Mr. Stone is qualified to serve on our Board of Directors because of his extensive experience developing early-stage biotech and healthcare companies.
As the Independent Director of Solid Biosciences Inc, the total compensation of Adam Stone at Solid Biosciences Inc is $87,965. There are 9 executives at Solid Biosciences Inc getting paid more, with Carl Morris having the highest compensation of $4,052,210.
Adam Stone is 41, he's been the Independent Director of Solid Biosciences Inc since 2015. There are 20 older and 2 younger executives at Solid Biosciences Inc. The oldest executive at Solid Biosciences Inc is Stephen J. DiPalma M.B.A., 62, who is the Treasurer & Principal Accounting Officer.
Adam's mailing address filed with the SEC is 51 Astor Place, 10th Floor, New York, NY 10003, United States.
Over the last 7 years, insiders at Solid Biosciences Inc have traded over $9,620,465 worth of Solid Biosciences Inc stock and bought 13,973,934 units worth $97,227,521 . The most active insiders traders include Advisors Llcperceptive Life..., Capital Management, L.P.Ra ..., eRajeev M. Shah. On average, Solid Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $1,822,871. The most recent stock trade was executed by Ian F Smith on 3 July 2024, trading 3,255 units of SLDB stock currently worth $24,380.
solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
Solid Biosciences Inc executives and other stock owners filed with the SEC include: